In an AD mouse model, it decreased the levels of microglial Tmem9 to inhibit the activation of complement, alleviated complement‐dependent synaptic loss, and eventually ameliorated emotional and cognitive disorders. This evidence concerns the gene TMEM9 and Alzheimer disease.